title: Favorable vessel healing after nobori biolimus A9-eluting stent implantation-6- and 12-month follow-up by optical coherence tomography.
abstract: BACKGROUND
  Nobori is a novel biolimus A9-eluting stent (BES) coated with a biodegradable polymer only on the abluminal side, which degrades over 6-9 months post-stent deployment. The course of vessel reaction after deployment at these time points remains unclear.
  
  
  RESULTS
  We serially evaluated 28 BES implanted in de novo coronary lesions of 23 patients using optical coherence tomography (OCT) at 6 and 12 months post-stenting. Standard OCT variables, the percentage of stent with peri-strut low-intensity area (PLIA, a region around stent struts homogenously showing lesser intensity than the surrounding tissue, suggesting fibrin deposition or impaired neointima maturation) and that with in-stent thrombi were evaluated. There was a significant, but small increase in neointimal thickness (72 ± 23 to 82 ± 25 µm, P=0.006) from the 6- to the 12-month follow-up, without a significant decrease in minimum lumen area (P=0.30). The incidences of uncovered and malapposed struts were low at 6 months and reduced further at 12 months (3.96 ± 3.97% to 1.51 ± 1.63%, P=0.001, and 0.50 ± 1.84% to 0.06 ± 0.24%, P=0.20, respectively). The frequency of stent with PLIA decreased during the follow-up (57% to 32%, P=0.05) and that with in-stent thrombi also numerically decreased (7% to 0%, P=0.24).
  
  
  CONCLUSIONS
  Neointimal hyperplasia was persistently suppressed following BES implantation up to 12 months. Simultaneously, favorable vessel healing was achieved at 6 months without a delaying adverse reaction for up to 12 months.
authors.affiliation: Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
authors.forename: Akihide
authors.initials: A
authors.lastname: Konishi
authors.forename: Toshiro
authors.initials: T
authors.lastname: Shinke
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Otake
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Takaya
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Takumi
authors.initials: T
authors.lastname: Inoue
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hariki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Osue
authors.forename: Yu
authors.initials: Y
authors.lastname: Taniguchi
authors.forename: Masamichi
authors.initials: M
authors.lastname: Iwasaki
authors.forename: Ryo
authors.initials: R
authors.lastname: Nishio
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Hiranuma
authors.forename: Hiroto
authors.initials: H
authors.lastname: Kinutani
authors.forename: Masaru
authors.initials: M
authors.lastname: Kuroda
authors.forename: Hachidai
authors.initials: H
authors.lastname: Takahashi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Terashita
authors.forename: Junya
authors.initials: J
authors.lastname: Shite
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000368:Aged; D063566:Biodegradable Plastics; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000473:pathology / Q000503:physiopathology; D012038:Regeneration; D020123:Sirolimus / Q000031:analogs & derivatives*; D041623:Tomography, Optical Coherence
chemical_list: D063566:Biodegradable Plastics; C518022:umirolimus; D020123:Sirolimus